Literature DB >> 1689129

Outcome of patients with cedar asthma with continuous exposure.

J Cote1, S Kennedy, M Chan-Yeung.   

Abstract

After an average follow-up of 6.5 yr (range 1 to 13), 48 of 48 patients with cedar asthma, who were still working in the same industry, were re-examined. In all of them, the diagnosis of cedar asthma had been confirmed with a specific challenge inhalation test with plicatic acid. We graded the severity of asthma symptoms and the requirement for antiasthma medications at the time of diagnosis and at the time of follow-up visit. Spirometry and measurement of airway responsiveness to methacholine (PC20 methacholine) were also done on both visits. The increase or decrease in asthma symptoms, medications requirement, FEV1 and PC20 methacholine between the follow-up and the diagnostic visit were used to determine the outcome of the patients. Using these parameters, 10.4% of patients improved, 62.5% remained stable, 37.5% deteriorated, and none recovered. Among the characteristics of the patients observed at the time of diagnosis, the age of the patient, the atopic status, smoking habit, and the presence of specific IgE to plicatic acid were not useful in predicting the eventual outcome. Reduction of exposure by transfer to a less dusty job and the use of an airstream helmet did not prevent deterioration of asthma. Only the use of the twin-cartridge respirator was associated with a favorable outcome. We conclude that among cedar asthmatics who remained exposed to cedar dust for an average of 6.5 yr, over one-third showed marked deterioration of their asthma symptoms. There is also no way to predict who will deteriorate. A decrease in the amount of exposure to cedar dust does not prevent deterioration of asthma. This suggests that the ideal management of cedar asthma is removal from exposure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689129     DOI: 10.1164/ajrccm/141.2.373

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

1.  Lung function decline in laboratory animal workers: the role of sensitisation and exposure.

Authors:  L Portengen; A Hollander; G Doekes; G de Meer; D Heederik
Journal:  Occup Environ Med       Date:  2003-11       Impact factor: 4.402

Review 2.  Asthma in the workplace: a Canadian contribution and perspective.

Authors:  Jean-Luc Malo; Moira Chan-Yeung
Journal:  Can Respir J       Date:  2007-10       Impact factor: 2.409

Review 3.  Occupational asthma. Practical points for diagnosis and management.

Authors:  W G Kuschner; R K Chitkara; P S Sarinas
Journal:  West J Med       Date:  1998-12

4.  Longitudinal decline in lung function in patients with occupational asthma due to western red cedar.

Authors:  F J Lin; H Dimich-Ward; M Chan-Yeung
Journal:  Occup Environ Med       Date:  1996-11       Impact factor: 4.402

Review 5.  Occupational reactions in the seafood industry.

Authors:  J L Malo; A Cartier
Journal:  Clin Rev Allergy       Date:  1993

6.  Outcome determinants for isocyanate induced occupational asthma among compensation claimants.

Authors:  S M Tarlo; D Banks; G Liss; I Broder
Journal:  Occup Environ Med       Date:  1997-10       Impact factor: 4.402

7.  Work-related respiratory symptoms and pulmonary function tests in northeast iranian (the city of Mashhad) carpenters.

Authors:  Mohammad Hossain Boskabady; Majid Khadem Rezaiyan; Iman Navabi; Sara Shafiei; Shahideh Shafiei Arab
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

8.  Toluene diisocyanate induced asthma: outcome according to persistence or cessation of exposure.

Authors:  G Pisati; A Baruffini; S Zedda
Journal:  Br J Ind Med       Date:  1993-01

9.  Grand rounds: latex-induced occupational asthma in a surgical pathologist.

Authors:  Judith Green-McKenzie; Debra Hudes
Journal:  Environ Health Perspect       Date:  2005-07       Impact factor: 9.031

10.  Respiratory impairment and systemic inflammation in cedar asthmatics removed from exposure.

Authors:  Chris Carlsten; Anne Dybuncio; Mandy M Pui; Moira Chan-Yeung
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.